Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. - sprookjes - yvandenbroek - TriplyDB

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

http://www.wikidata.org/entity/Q39313889

about

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.CyTOF Measurement of Immunocompetence Across Major Immune Cell Types.Patent trend and competitive analysis of cancer immunotherapy in the United States.Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.T cell densities in brain metastases are associated with patient survival times and diffusion tensor MRI changes.Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.Discovery and application of immune biomarkers for hematological malignancies.The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.Antitumor in situ vaccination effect of TNFα and IL-12 plasmid DNA electrotransfer in a murine melanoma model.Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma Advanced model systems and tools for basic and translational human immunology

P2860

Q41107790-4B5549C6-C567-4F32-94C0-BE209E55EFF7 Q41899044-B7AD3FD7-4DED-45D3-99FD-F5AB0FAB1F66 Q45930699-5602CEF9-9460-4776-9502-781FE6DCF2D9 Q46310803-ABE838DD-8FDD-4EB9-AA17-8682BBDAB6E7 Q46449589-05A0BC1C-7D97-44FF-882F-483C14333027 Q47322246-A835F961-3339-43AD-964F-263ACEDB36A6 Q47399053-16E86DF4-0A01-4893-8B60-2446CEB896D4 Q47422615-196F886E-08BE-4E8F-A04E-D5694AC59596 Q47681393-320FB459-110D-4DC1-AB51-9F119B80C9B3 Q49885285-0F3E0109-7878-4E49-AD12-FD62F1485DE9 Q52365353-8CC81499-7EA4-4CDF-8420-36364E640690 Q52718431-A271F3C3-43E3-4209-B05B-16EB3A445D4E Q54268953-BAD3D33B-36DC-4A12-B7EA-25D42D46E092 Q55029432-5D426A25-5750-471B-BAA3-3F7D10825912 Q55297626-05988AD6-AD39-424B-83C6-3700B6359C45 Q57062487-CF675FBE-434C-4E7C-99AE-7B8F0D31E508 Q57069521-54C8FF4D-A02B-4576-94BE-B9EAFD1BE26B Q58742661-16819470-A56C-4DEB-8116-541D222C06CD Q59126043-113A1A38-7427-43FF-93B9-0EABD24B2C11

P2860

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

http://www.wikidata.org/entity/Q39313889

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Identifying baseline immune-re ...... ical outcome of immunotherapy.

@en

Identifying baseline immune-re ...... ical outcome of immunotherapy.

@nl

type

label

Identifying baseline immune-re ...... ical outcome of immunotherapy.

@en

Identifying baseline immune-re ...... ical outcome of immunotherapy.

@nl

prefLabel

Identifying baseline immune-re ...... ical outcome of immunotherapy.

@en

Identifying baseline immune-re ...... ical outcome of immunotherapy.

@nl

P1433

Q39313889-9724096E-0412-4645-9DB3-93446BE66BAC

P1476

Q39313889-1409FE9D-3538-4F78-86E2-4D340ABCA2A7

P2093

Q39313889-077F0103-260A-4CA7-A14C-16649DC26656

Q39313889-07E9132B-2823-422B-99EB-69712065ECE3

Q39313889-16E42CA0-E992-4519-B12C-3D336E950A61

Q39313889-2E052F2A-AEB4-4798-8B6C-64E3C96AB609

Q39313889-3E9B9A8F-D7E8-4C54-A320-782CCAEE9986

Q39313889-3F0735C7-CEA5-49A9-9F19-FE9B18BAB4D9

Q39313889-6DEE357E-D9BC-4E12-A85F-2AEE9CF70102

Q39313889-88CC24FC-C074-43D4-81EB-54E12B5D5475

Q39313889-906D641E-F743-4EAD-8870-F066CCE50897

Q39313889-923EC960-05B5-4E64-A2B8-38BDE72477C0

P275

Q39313889-A195FF3C-4B3C-4D4E-BF67-A0F5A75534A3

P2860

Q39313889-00381034-6319-4309-9C8A-562EB5A6152A

Q39313889-00C8D4AB-AD1E-4230-B56F-C8774089F4F1

Q39313889-01E81019-111A-4268-A104-3E4C3147B2CF

Q39313889-03296D9A-FC6F-41C3-A3BF-2E07B7520C90

Q39313889-0917F8BF-1254-4700-BBAA-C2563FE1CF7C

Q39313889-098C571A-AAEB-43E7-82EA-40B53FEF4E8D

Q39313889-09F86E33-F319-4FC5-873F-ECCD1B72EF8B

Q39313889-0D313852-E273-42F4-BB7E-5474591FC324

Q39313889-0E9E8930-B0D5-46A5-AC6D-C900BC120BFD

Q39313889-1045E0CD-2645-4222-B7C6-7C0B326D4AB3

P2888

Q39313889-426F4F1F-0A15-438D-98BC-9A14F291FA5D

P304

Q39313889-9421D40F-0DF3-4451-9E0B-07E0E5976EEF

P31

Q39313889-1BBCDAA3-D550-459A-9A6B-9E88CB6ACD9E

Q39313889-F9485C35-7366-4120-A9ED-8C2BEC19EE74

P356

Q39313889-3C0DE531-CAF5-468E-91DC-05F0D8B55FA7

P478

Q39313889-52A8F4CE-C722-438B-AE10-B1726C9226AD

P50

Q39313889-0370F1D4-2EFC-4478-8175-4ACB5F9E76DE

Q39313889-86F5FC2E-B502-4719-8D15-07685192CDF1

Q39313889-DB696D67-CDF9-4E57-9A24-9453844C1FCE

P5008

Q39313889-9CD08BE6-2B01-4A6B-9C67-C1EF2E7584D4

P577

Q39313889-B89C22AA-84CB-4915-B76E-B2CB5AB1D352

P6179

Q39313889-27E44B68-A0BD-44C9-914F-84A06B6C6B56

P698

Q39313889-D0874471-B9B2-43C1-A6D3-6BE056F24982

P921

Q39313889-40CF9D7A-D427-457E-80E9-C969333450F8

Q39313889-5372394E-FD76-45F2-861C-8369C93738C7

Q39313889-C4E76BD8-8FE3-4757-A137-958159E20CEA

Q39313889-DFCD7EE0-143B-415F-82F3-AAB40C873C78

P932

Q39313889-2973CE98-3A2B-4628-8AAD-5A6BE5A8799C

P356

S40425-017-0243-4

P1433

Journal for Immunotherapy of Cancer

P1476

Identifying baseline immune-re ...... ical outcome of immunotherapy.

@en

P2093

Dolores J Schendel

http://www.w3.org/2001/XMLSchema#string

Isabelle Tanneau

http://www.w3.org/2001/XMLSchema#string

John M Kirkwood

http://www.w3.org/2001/XMLSchema#string

Jon M Wigginton

http://www.w3.org/2001/XMLSchema#string

Laura Rosa Brunet

http://www.w3.org/2001/XMLSchema#string

Leif G Hakansson

http://www.w3.org/2001/XMLSchema#string

Lisa H Butterfield

http://www.w3.org/2001/XMLSchema#string

Marcus O Butler

http://www.w3.org/2001/XMLSchema#string

Mary L Disis

http://www.w3.org/2001/XMLSchema#string

Sacha Gnjatic

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Cancer classification using the Immunoscore: a worldwide task force

Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations

Interferon alpha for the adjuvant treatment of cutaneous melanoma

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Single-cell technologies are revolutionizing the approach to rare cells

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

P2888

s40425-017-0243-4

P304

44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-017-0243-4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2017-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085379251

http://www.w3.org/2001/XMLSchema#string

P698

28515944

http://www.w3.org/2001/XMLSchema#string

P921

tumor biomarkers

P932

5432988

http://www.w3.org/2001/XMLSchema#string